Litcius/Paper detail

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

Dirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, Inge De Lepeleire, Martine Robberechts, Evan Friedman, Christian Keicher, Andreas Hüser, Jörg Hofmann, Jay A. Grobler, S. Aubrey Stoch, Marian Iwamoto, Randolph P. Matthews

2020The Lancet HIV95 citationsDOI

Topics & Concepts

MedicinePharmacokineticsReverse-transcriptase inhibitorTolerabilityDosingNucleoside Reverse Transcriptase InhibitorAdverse effectPharmacologyInternal medicineLamivudineExpanded accessViral loadImmunologyHuman immunodeficiency virus (HIV)VirusAntiretroviral therapyHepatitis B virusHIV/AIDS drug development and treatmentHIV Research and TreatmentHIV-related health complications and treatments
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial | Litcius